Cons Of 'Brexit' For Pharma Could Far Outweigh Pros
Executive Summary
The pharma and health policy consequences of a possible "Brexit" – i.e. the departure of the U.K. from the European Union – were discussed by a variety of stakeholders earlier this month. The U.K.'s recent general gave Prime Minister David Cameron a mandate to hold an EU referendum by the end of 2017.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.